Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8852W HIGH $15.87
Volume
97.36 K
Value Traded
24.10 M
Short % Float
12.97%
Days to Cover
6.8
+4.71%Week
-0.26%1 Month
+2.84%3 Month
+21.53%6 Month
-67.01%5 Year
-49.53%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.60 B
EPS (TTM)
-2.85
P/E Ratio
-
Ent. Value
1.22 B
Total Shares
138.48 M
Float Shares
136.24 M
Insiders
1.61%
Institutions
66.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CMPS Catalyst Timeline
Dated clinical, regulatory and corporate events for COMPASS Pathways Plc - American Depository Shares
Catalyst Timeline
Dated clinical, regulatory & corporate events for COMPASS Pathways Plc - American Depository Shares
100Total events
13Upcoming
24Tier-1 (high impact)
2020 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Timing GuidancePresentation
Compass Pathways launches 'Change the Tune in TRD' U.S. HCP disease education initiative
treatment-resistant depressionsource ↗
▲Grant / FundingCOMP360Corporate
Strata Mental Health Solutions awarded one of five U.S. HCP training grants from Compass Pathways for COMP360 provider training
▲Grant / FundingCOMP360Corporate
Fluence selected by Compass Pathways as recipient of U.S. healthcare provider training grant program
treatment-resistant depressionsource ↗
▲Topline ReadoutCOMP360Clinical Data
Topline 52-week (Part C) results from Phase 3 COMP005 trial of COMP360 in TRD
treatment-resistant depression (TRD)source ↗
▲Long Term DataCOMP360Clinical Data
52-week durability data from Phase 3 COMP005 Part C demonstrating benefit extended out to 1 year
treatment-resistant depression (TRD)source ↗
▲Safety Data UpdateCOMP360Clinical Data
COMP360 safety profile in Part C consistent with Parts A and B, no new safety findings
treatment-resistant depression (TRD)source ↗
●R&D DayPresentation
Compass Pathways to participate in 2026 Cantor Global Healthcare Conference
●Oral PresentationPresentation
Debut of 'Change the Tune in TRD' HCP education campaign at Psych Congress 2026
treatment-resistant depression (TRD)source ↗
●Poster PresentationPresentation
Presentation of new HEOR data examining burden of TRD at Psych Congress 2026
treatment-resistant depressionsource ↗
●Poster PresentationCOMP360Presentation
Encore presentations from COMP360 program at Psych Congress 2026
treatment-resistant depressionsource ↗
●Timing GuidancePresentation
Debut of Change the Tune in TRD U.S. HCP education campaign
treatment-resistant depressionsource ↗
●R&D DayPresentation
Compass Pathways to participate in Canaccord Genuity's 46th Annual Growth Conference
◆Trial InitiationCOMP360Trial
Collaboration with VA for multi-site trial of COMP360 in veterans with TRD
treatment-resistant depressionsource ↗
▲Full ResultsCOMP360Clinical Data
26-week results from COMP006 Part B
treatment-resistant depressionsource ↗
●Oral PresentationCOMP360Presentation
Live webcast on July 7 at 8:00 am ET
treatment-resistant depressionsource ↗
◆Oral PresentationPresentation
Compass Pathways to participate in Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Compass Pathways to participate in RBC Capital Markets Global Healthcare Conference
◆Oral PresentationPresentation
Compass Pathways to Participate in Needham Virtual Psychedelics Forum
▲Partnership / LicenseCorporate
Collaboration with Osmind to advance clinic readiness for psychedelic treatments
▲Rolling Submission InitiatedCOMP360Regulatory Filing
FDA granted rolling NDA submission and review request for COMP360
Treatment-Resistant Depression (TRD)source ↗
▼Equity OfferingCorporate
Public offering closed on February 20, 2026, net proceeds ~$141 million
▼Equity OfferingCorporate
Launches proposed $150.0 million public offering of ADSs and pre-funded warrants
◆Topline ReadoutCOMP360Clinical Data
New clinical data from Part A and Part B of COMP005
treatment-resistant depressionsource ↗
◆Oral PresentationCOMP360Presentation
Webinar hosted by Compass management to discuss new clinical data
treatment-resistant depressionsource ↗
▲Primary Endpoint MetCOMP360Clinical Data
COMP006 Phase 3 trial met primary endpoint with p<0.001 and -3.8 point MADRS difference
treatment-resistant depressionsource ↗
●Trial CompletionCOMP360Trial
COMP005 Part B (blinded through week 26) recently concluded
treatment-resistant depressionsource ↗
▲Topline ReadoutCOMP360Clinical Data
Positive Phase 3 COMP005 data in TRD reported
Treatment-Resistant Depression (TRD)source ↗
▲PublicationCOMP360Presentation
Peer-reviewed post-hoc analysis of COMP360 Phase 2b PTSD sessions published in Journal of Psychopharmacology
Post-Traumatic Stress Disorder (PTSD)source ↗
◆Topline ReadoutCOMP360Clinical Data
Topline data expected from COMP005 Phase 3 trial in TRD
treatment-resistant depressionsource ↗
◆Topline ReadoutCOMP360Clinical Data
Topline primary analysis for COMP 006 expected mid 2025
treatment-resistant depressionsource ↗
◆Timing GuidanceCOMP360Presentation
Initial data from COMP360 phase 3 program in TRD expected summer 2024
treatment-resistant depressionsource ↗
◆Topline ReadoutCOMP360Clinical Data
Topline primary analysis for COMP 005 expected Summer 2024
treatment-resistant depressionsource ↗
◆Management ChangeCorporate
Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia step down from board of directors
◆Management ChangeCorporate
Appointment of Teri Loxam as Chief Financial Officer effective March 2024
◆Topline ReadoutCOMP360Clinical Data
Topline data expected end 2024 for COMP 005
treatment-resistant depressionsource ↗
Past FDA Catalysts and PDUFA Decisions
How CMPS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-07 | COMP360 (synthetic, proprietary formulation of psilocybin) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 28%
Micro Cap(rank 189 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| COMP360 Small moleculeNCT05711940 | Treatment Resistant Depression | Phase 3 | ACTIVE NOT_RECRUITING | 1,082 | Dec 1, 2026 | ||||||
| COMP360 Small moleculeNCT05733546 | Major Depressive Disorder | Phase 2 | ACTIVE NOT_RECRUITING | 122 | Sep 1, 2025 | ||||||
| COMP360 psilocybin Small moleculeNCT07570654 | PTSD - Post Traumatic Stress Disorder | Phase 2/3 | RECRUITING | 300 | Sep 1, 2029 | ||||||
| COMP360 Small moleculeCompletedNCT05312151 | Post Traumatic Stress Disorder | Phase 2 | COMPLETED | 22 | Feb 12, 2024 | ||||||
| COMP360 Small moleculeCompletedNCT05481736 | Anorexia Nervosa | Phase 2 | COMPLETED | 48 | Nov 18, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every CMPS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| COMP360 Breakthrough | treatment-resistant depression | Phase 3 | 2026-09-09 | 52-week resultsRead More | Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 YearRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Karydas DaphneDirector | Grant/Award | 21,110 21,110 held | $0.00 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CMPS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 2.5 % (127.3 %) | 172.09 M | 12.16 M |
Ownership Trends
CMPS Short Interest
Shares sold short, counted twice a month.
12.97%
Short % of Float
of tradable shares sold short
17.7M
Shares Sold Short
+3.7% vs prior count
6.8 High
Days to Cover
trading days of normal volume to buy every short share back
2.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CMPS ranks across every disease it competes in
Competitive Position is a premium feature
See how CMPS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCMPS News
CMPS▼ -0.5%today
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
Compass Pathways and the Depression and Bipolar Support Alliance released a report detailing the impact of treatment-resistant depression (TRD) on patients and caregivers. The national survey included responses from 261 individuals with TRD and 73 caregivers, highlighting the significant daily challenges faced by those affected. The findings aim to inform better treatment options in mental health care.
Read more →CMPSCompass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
Compass Pathways will participate in the 2026 Neuroscience Education Institute Fall Congress, focusing on treatment-resistant depression (TRD). The company will present its educational campaign, 'Change the Tune in TRD,' and encore presentations from its COMP360 psilocybin clinical program. This event aims to enhance understanding among U.S. healthcare professionals.
Read more →CMPS▲ +6.9%on this newsshared move
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
Compass Pathways plc will announce its third quarter 2026 financial results on November 3, 2026. The company will also provide updates on recent developments during a conference call at 8:00 am ET. Compass is focused on developing COMP360 psilocybin for treatment-resistant depression and PTSD, with significant designations from regulatory bodies.
Read more →CMPSCompass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
Compass Pathways has announced the first-ever Treatment-Resistant Depression (TRD) Awareness Day in the U.S., aimed at raising awareness about the condition and its impact on patients and caregivers. The initiative is supported by major mental health organizations and seeks to foster understanding and support for those affected by TRD. A report detailing the burden of TRD will be released in the future.
Read more →CMPSCompass Pathways Celebrates Opening of New U.S. Office in Jersey City, New Jersey
Compass Pathways has inaugurated its new U.S. office in Jersey City, New Jersey, which will serve as a hub for its employees in the tri-state area. This 6,327-square-foot facility aims to support the company's efforts in advancing its investigational treatment, COMP360, for treatment-resistant depression. The CEO highlighted the importance of this milestone in the company's growth and commitment to improving mental health care.
Read more →CMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways plc has announced the granting of equity awards to a senior leader and ten new non-executive employees under its 2026 Inducement Plan. This move reflects the company's strategy to enhance its leadership and workforce as it focuses on developing new treatment options in mental health care. The equity awards for the senior leader include options to purchase a total of 121,800 shares.
Read more →CMPSCompass Pathways Appoints Kelley Boucher as Chief People Officer
Compass Pathways has appointed Kelley Boucher as Chief People Officer, effective immediately. This strategic move aims to strengthen the executive team as the company focuses on scaling its operations. The appointment aligns with Compass's mission to introduce innovative psychedelic treatments in psychiatry.
Read more →CMPSCompass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
Compass Pathways plc will participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company will host a fireside chat at 1:00 pm ET, which will be available via a live audio webcast. Compass is focused on developing innovative treatments for mental health, including its investigational psilocybin treatment, COMP360.
Read more →CMPS▼ -5%on this newsshared move
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
Compass Pathways has launched the 'Change the Tune in TRD' initiative aimed at enhancing healthcare provider understanding of treatment-resistant depression (TRD). This campaign will delve into the neurobiology of TRD and assist in navigating care pathways for both patients and providers. The initiative was announced during the Psych Congress 2026.
Read more →CMPSStrata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360
Strata Mental Health Solutions has received a grant from Compass Pathways to develop training programs for healthcare providers regarding COMP360, an investigational psilocybin treatment. This initiative aims to prepare clinical networks for the potential delivery of psychedelic treatments. The collaboration highlights Strata's expertise in the field.
Read more →CMPS▼ -6.3%on this newsshared move
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Fluence has been selected by Compass Pathways to develop a certificate program for healthcare providers in anticipation of the FDA's approval of COMP360, a psilocybin treatment for depression. The program will consist of three modules aimed at equipping clinicians with the necessary skills and knowledge to support patients. This collaboration emphasizes Fluence's dedication to translating research into clinical practice.
Read more →CMPS▼ -6.3%on this newsshared move
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
Compass Pathways has announced the recipients of its U.S. grant program aimed at developing training for healthcare providers to deliver COMP360, a psilocybin treatment for treatment-resistant depression. The program awarded grants to five organizations, expanding from the initial plan of three due to high-quality applicants. This initiative is part of Compass's commitment to ensuring effective treatment delivery upon COMP360's potential approval.
Read more →CMPS▼ -6.3%on this newsshared move
Compass Pathways to Participate in Investor Conferences the Week of September 14th
Compass Pathways plc will participate in investor conferences during the week of September 14th. The company aims to engage with investors at the H.C. Wainwright Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. These events will provide a platform for discussing their innovative approaches in mental health care.
Read more →CMPS▲ +8%on this newsshared move
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
Compass Pathways has released topline results from the Phase 3 COMP005 trial of COMP360, a psilocybin formulation for treatment-resistant depression. The open-label Part C data indicates an additional benefit from another dose, extending the treatment's durability to one year. This supports the drug's differentiated profile and potential for long-term effectiveness.
Read more →CMPS▲ +5.8%on this newsshared move
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
Compass Pathways is set to launch its 'Change the Tune in TRD' education campaign at Psych Congress 2026, focusing on treatment-resistant depression (TRD). The company will also present new health economics and outcomes research data, alongside findings from its COMP360 psilocybin clinical trials. This initiative aims to enhance healthcare provider education on TRD.
Read more →CMPSCompass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
Compass Pathways has been honored as a 2026 Fierce 50 Breakthrough honoree, highlighting its commitment to advancing treatment options in mental health care. This recognition by Fierce Pharma, Fierce Biotech, and Fierce Healthcare underscores the company's role in fostering innovation and shaping the future of biopharma. The award celebrates organizations making significant contributions to medicine.
Read more →CMPSCompass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
Compass Pathways plc will participate in the 2026 Cantor Global Healthcare Conference on September 9, 2026. The company will host a fireside chat and join a panel discussing psychedelics in mental health treatment. This engagement underscores their commitment to exploring new therapeutic options.
Read more →CMPSCompass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
Compass Pathways plc has announced its participation in the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026. The management will also engage in a fireside chat at 8:00 am ET. Additionally, they will attend the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026, showcasing their commitment to investor relations.
Read more →CMPSCompass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
Compass Pathways is collaborating with the U.S. Department of Veterans Affairs on a multi-site randomized controlled clinical trial. This study aims to evaluate the safety and efficacy of COMP360 psilocybin for treating treatment-resistant depression in veterans, particularly those experiencing post-traumatic stress.
Read more →About COMPASS Pathways Plc - American Depository Shares
Headquarters3RD FLOOR, 1 ASHLEY ROAD, CHESIRE, X0, WA14 2DT
BIOPHARMAWATCH ELITE PLUS
Trade the next CMPS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime